BRIEF—Boehringer replaces head of US subsidiary

German family-owned pharma major Boehringer Ingelheim announced today that Paul Fonteyne, US president and chief executive, will retire after 15 years of service on December 31, 2018.

Wolfgang Baiker has been appointed to succeed him, effective March 1, 2018.

Dr Baiker, currently senior vice president, human pharma supply and global quality and head of the Biopharma Business Unit, joined Boehringer Ingelheim in 1989 as section head for clinical development in Biberach, Germany.

Since then, Dr Baiker has served in a number of senior leadership roles across several critical business functions,

Mr Fonteyne will now be turning his full attention for the remainder of the year to leading the US Animal Health business, where he will continue to oversee the integration and normalizing of operations following the acquisition of Merial from Sanofi last year.

He will also remain chairman of the Boehringer Ingelheim USA Board.